aTyr Pharma appoints Eric Benevich to board; amends director compensation policy

aTYR PHARMA INC

Eric Benevich appointed as Class II director effective Dec 10, 2024, term through 2026 annual meeting.
Granted option to purchase 100,000 shares at Dec 10 closing price, vesting equally over 36 months.
Amended Non-Employee Director Compensation Policy: annual retainer $40,000; committee fees $5,000–$20,000.
Initial equity grant for new non-employee directors set at 100,000 options; annual grant 50,000 options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.